The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scienfific findings into the clinic. WON Members study novel pathways by which hormones and growth factors regulate growth and metastasis of women's cancers;identify potential new therapeufic targets or prognostic indicators for response or resistance to therapy;and perform clinical trials to test efficacy of therapeutic agents in treating these cancers. Program leadership has organized WON around three research themes: (1) steroid hormone action and steroid-dependent cancers;(2) growth factor and cytokine promotion of tumor development and metastasis;and (3) invesfigator-initiated clinical research and development of novel clinical research tools. Professor of Medicine and Physiology Margaret A. Shupnik, PhD, and Professor of Medicine Paula M. Fracasso, MD, PhD, lead the Program. Dr. Shupnik has expertise in molecular endocrinology and estrogen receptor action, and Dr. Fracasso is an experienced clinical trialist in women's oncology. The Program represents a wide variety of expertise: 22 Members from nine departments in the schools of Medicine and of Engineering, and six Associate Members. With critical CCSG help, seven WON Members have joined the University of Virginia (UVA) since the last renewal, and two Members have been retained. The following areas of support have enabled the success of WON research initiatives, which have become increasingly cancer focused and interactive: funding for faculty recruitment and retention;funding for informafion exchange forums, such as the CC Seminar Series, WON research meetings, and the Program Retreat;Cancer Center Pilot Project Funds;and support from the UVA Cancer Center Shared Resources. Total extramural funding for the Program exceeds $10.5 million, including nearly $5 million from the Nafional Cancer Institute (NCI). Over the past five years, WON Members have published 317 Program-relevant papers of which 29% were inter-Programmatic and 21% were intra-Programmatic.
; The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scientific findings into the clinic.
|Heuslein, Joshua L; Murrell, Kelsey P; Leiphart, Ryan J et al. (2016) Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion. Sci Rep 6:27029|
|Ma, Zhenjun; Kim, Youngchul; Hu, Feifang et al. (2016) Point success rate for patient therapeutic response prediction by continuous biomarker scores. Stat Methods Med Res 25:1638-47|
|Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201-12|
|Pelkofski, Elizabeth; Stine, Jessica; Wages, Nolan A et al. (2016) Cervical Cancer in Women Aged 35 Years and Younger. Clin Ther 38:459-66|
|Showalter, Timothy N; Camacho, Fabian; Cantrell, Leigh A et al. (2016) Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 95:e2913|
|Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol Immunother 65:1189-99|
|Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859|
|Kolpaczynska, Milena; DeRosa, Christopher A; Morris, William A et al. (2016) Thienyl Difluoroboron Î²-Diketonates in Solution and Polylactide Media. Aust J Chem 69:537-545|
|Sloane, Hillary S; Landers, James P; Kelly, Kimberly A (2016) Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. J Mol Diagn 18:546-53|
|Cheng, Bei; He, Huacheng; Huang, Tao et al. (2016) Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. J Biomed Nanotechnol 12:435-49|
Showing the most recent 10 out of 413 publications